Now referred to as Repligen/Pfizer compound RG3039, this SMN2 promoter activator only modestly increases SMN mRNA and SMN protein levels in various mouse models of severe and mild SMA [88–90]. Here, SMN1 is linked to proximal spinal muscular atrophy.